Panchal et al. [21] reported that new derivatives (17d, 16j, and 16h) of bosentan, an endothelin receptor antagonist, can dose-dependently reduce HIF-1α levels in vivo studies using monocrotaline (MCT) induced PAH in a rat model. The gene discussed is HIF1A; the disease is pulmonary arterial hypertension.